All Insights

A $100M fund only deploys $80M — management fees are extracted before a single investment is made, yet LPs must generate returns on the full $100M. Here's the structural asymmetry between who provides the capital and who controls it. Article 2 of 4 in the Venture Capital Reality Series.

A VC fund that avoided its two riskiest bets would have returned 0.42x instead of 2.5x. Why "playing it safe" is the riskiest strategy in venture capital. Article 1 of 4 in the Venture Capital Reality Series.

A $2M investment at $8M pre-money gives 20% ownership; at $18M pre-money, just 10% — same check, completely different outcome. A full walkthrough of startup valuation mechanics using a fictional case study, from pre-money math to the hidden cost of option pool timing.

Angel checks range $25K-$350K, VC spans $500K seed to $200M late-stage, PE requires $50M+ ARR — and investment banks aren't investors at all. A full map of who funds what, at each stage, and how to actually reach them.

Leading AI companies deliberately avoid patenting their core techniques — choosing trade secrecy instead, since public disclosure would hand competitors a roadmap. Why "moat" means something different in hardware, software, and AI.

Moderna had no patent, no clinical data — just one peer-reviewed paper. J&J's vaccine used a far more mature, proven platform, and was pulled after $1.5B in losses. Why the safer-looking bet doesn't always win.

QQQ holders gained SpaceX exposure within 15 days of its June 2026 IPO. VOO holders won't own it until mid-2027 at the earliest — and VGT/SMH holders never will. A look at the committees that quietly decide what's actually in your index fund.

Value beat growth in 6 of 9 decades since the 1930s — this decade is only the second sustained exception. And a big piece of "growth winning" may really just be NVIDIA, now over 13% of VONG, dressed in index language.

SMH compounded at ~36% annualized over the past decade — but with an 85% max drawdown that requires a 550%+ gain just to break even. A look at how VOO, VOOG, VONG, VGT, and SMH trade diversification for return, one narrowing step at a time.

AI drug discovery has one validated success and zero FDA approvals so far — while AI in trial design already has formal regulatory qualification from both the EMA and FDA. The most-hyped application in pharma AI isn't the one furthest along.